ESPERION Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Company Update
February 23, 2021 16:01 ET
|
Esperion Therapeutics, Inc.
Fourth Quarter 2020 U.S. Product Revenue of $8.2 Million, Approximately 150 Percent Increase Compared to the Third QuarterOver 21,000 Patients on NEXLETOL® (bempedoic acid) and NEXLIZET® (bempedoic...
ESPERION Appoints Sheldon Koenig as Chief Operating Officer
December 15, 2020 07:00 ET
|
Esperion Therapeutics, Inc.
ANN ARBOR, Mich., Dec. 15, 2020 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced the appointment of Sheldon Koenig, a proven leader in the cardiovascular market, as chief operating...
Esperion Announces Private Offering of $200.0 Million of Convertible Senior Subordinated Notes
November 10, 2020 16:30 ET
|
Esperion Therapeutics, Inc.
ANN ARBOR, Mich., Nov. 10, 2020 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced its intention to offer, subject to market conditions and other factors, $200.0 million aggregate principal...
Esperion Announces Commercial Availability of NEXLIZET™ (bempedoic acid and ezetimibe) Tablets and Ushers in New Era of Oral Combination Medicine for LDL-Cholesterol Lowering
June 04, 2020 07:00 ET
|
Esperion Therapeutics, Inc.
– First-Ever Non-Statin Combination Medicine, Providing 38 Percent Mean LDL-C Lowering – – Esperion Aims to Set New Industry Standard by Pricing NEXLIZET for Patient Affordability and Access with...
Bempedoic Acid Included in Top 10 Medical Innovations for 2020 List
October 25, 2019 10:00 ET
|
Esperion Therapeutics, Inc.
ANN ARBOR, Mich., Oct. 25, 2019 (GLOBE NEWSWIRE) -- Esperion (NASDAQ:ESPR) announced that bempedoic acid was included in the “Top 10 Medical Innovations for 2020” at Cleveland Clinic’s 2019 Medical...
Esperion Announces FDA Confirmation of Regulatory Pathway to Approval for the Combination of Bempedoic Acid and Ezetimibe
June 26, 2017 16:05 ET
|
Esperion Therapeutics, Inc.
– Complementary, Non-statin, Oral Bempedoic Acid / Ezetimibe Combination Therapy Demonstrates 48% Lowering of LDL-C and Significant hsCRP Reduction with Potential for Lower Occurrence of...
Esperion Provides Update on Common Stock Trading Activity
May 22, 2017 08:05 ET
|
Esperion Therapeutics, Inc.
ANN ARBOR, Mich., May 22, 2017 (GLOBE NEWSWIRE) -- Esperion Therapeutics, Inc. (NASDAQ:ESPR), the Lipid Management Company focused on developing and commercializing convenient, complementary,...
Esperion to Participate in Fireside Chat at the UBS Global Healthcare Conference
May 19, 2017 16:30 ET
|
Esperion Therapeutics, Inc.
Fireside Chat Webcast on Tuesday, May 23, 2017 at 9:00 a.m. Eastern Time ANN ARBOR, Mich., May 19, 2017 (GLOBE NEWSWIRE) -- Esperion Therapeutics, Inc. (NASDAQ:ESPR), the Lipid...
Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
May 18, 2017 16:30 ET
|
Esperion Therapeutics, Inc.
ANN ARBOR, Mich., May 18, 2017 (GLOBE NEWSWIRE) -- Esperion Therapeutics, Inc. (NASDAQ:ESPR), the Lipid Management Company focused on developing and commercializing convenient, complementary,...
Esperion to Participate in Fireside Chat at the Bank of America Merrill Lynch 2017 Healthcare Conference
May 12, 2017 16:30 ET
|
Esperion Therapeutics, Inc.
Fireside Chat on Wednesday, May 17, 2017 at 3:40 p.m. Pacific Time/6:40 p.m. Eastern Time ANN ARBOR, Mich., May 12, 2017 (GLOBE NEWSWIRE) -- Esperion Therapeutics, Inc. (NASDAQ:ESPR), the Lipid...